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Abstract
Background: The PANDORA study has recently examined the prevalence of low ankle brachial index (ABI) in
subjects with moderate risk of cardiovascular disease. This sub-analysis of the PANDORA study examines the
prevalence of asymptomatic peripheral arterial disease (PAD), as determined by ABI, in Italian subjects presenting
with moderate cardiovascular risk, in the absence of diabetes or overt vascular disease.
Methods: PANDORA is a non-interventional, cross-sectional study that was performed in 6 European countries,
involving subjects with at least one cardiovascular (CV) risk factor. The primary objective was to evaluate the
prevalence of asymptomatic PAD using ABI. For this post-hoc sub-analysis, data were extracted for subjects
enrolled in Italy, comprising 51.5% (n = 5298) of subjects from the original PANDORA study. Secondary objectives
were to establish the prevalence and treatment of CV risk factors.
Results: The mean age was 63.9 years and 22.9% (95% CI 21.7-24.0) of subjects presented with asymptomatic PAD.
A range of risk factors comprising smoking, hypertension, low HDL-cholesterol, family history of coronary heart
disease and habit of moderate-high alcohol intake were significantly associated with asymptomatic PAD (p <
0.0001). Statin treatment had the lowest incidence in Italian subjects. Furthermore, patients treated with statins
were significantly less likely to have asymptomatic PAD than those who were not (p = 0.0001).
Conclusions: Asymptomatic PAD was highly prevalent in Italian subjects, the majority of whom were not
candidates for ABI assessment according to current guidelines. Findings from this study suggest that these patients
should be carefully examined in clinical practice and ABI measured so that therapeutic interventions known to
decrease their CV risk may be offered.
Trial registration number: ClinicalTrials.gov: NCT00689377
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Individuals who are diagnosed with lower extremity per-
ipheral arterial disease (PAD) are associated with a
reduced quality of life, in addition to an increased risk of
atherosclerosis, stroke, cardiovascular (CV) morbidity and
mortality [1-3]. Unfortunately the CV burden associated
with the presence of PAD is similar, regardless of whether
it is the asymptomatic or symptomatic form of PAD [4,5].
For this reason, current guidelines recommend the mea-
surement of ankle-brachial index (ABI) to identify asymp-
tomatic patients and allow early and appropriate clinical
and therapeutic intervention thus reducing their increased
risk of CV-related mortality [1,6,7]. ABI is recognised as a
method that is accurate and reliable in the diagnosis of
PAD, compared to angiography and Doppler ultrasound
[8-10]. However, although ABI is easily assessable, this
technique is poorly utilised in general practice and PAD is
still a disease that continues to be under diagnosed and
under treated [11]. Moreover, few studies are actually
available with an adequate sample size to accurately
describe the prevalence of low ABI in the adult population
with moderate CV risk, as defined in NCEP ATP-III
guidelines [7,12].
ABI has recently been evaluated for its use in improving
the accuracy in prediction of CV risk in combination with
the Framingham Risk Score (FRS), compared to the use of
FRS alone [13]. This study demonstrated that a low ABI
(≤0.90) was associated with a significant increase in the
rate of CV morbidity and mortality compared with the
overall rate for FRS. Due to the low prevalence of PAD
within this patient group, the U.S. Preventive Services
Task Force recommends against routine screening for
PAD in asymptomatic individuals [14], as screening for
PAD in the general population would have few or no ben-
efits. However, current knowledge concerning the epide-
miology of PAD is mainly limited to studies carried out in
northern European and northe r nA m e r i c a np o p u l a t i o n s
[15-19], and, only more recently, 2 studies performed in
southern European countries [20-22]. Recently, due to the
increasing weight of evidence on the use of the ABI to pre-
dict cardiovascular morbidity and mortality, current Task
Force guidelines now supports the measurement of ABI in
patients at risk of PAD [23]. Since epidemiological data for
atherosclerotic disease may be markedly affected by a
range of factors, including genetics, ethnics, diet, lifestyle/
environment etc., it is therefore also plausible that the pre-
valence and natural history of PAD in Southern European
countries may differ from that of Northern European
countries. Actually, to date, just one Italian prevalence
study has been performed on the symptomatic PAD popu-
lation [20]. The aim of this study was to examine the pre-
valence of asymptomatic PAD using ABI, in subjects with
moderate risk of cardiovascular disease (CVD) in the Ita-
lian population.
Methods
The methods and main findings from the PANDORA
study have been published elsewhere [24,25]. In brief,
PANDORA was a non-interventional cross sectional study
performed across 6 European countries (Italy, Belgium,
France, the Netherlands, Greece and Switzerland), that
examined the prevalence of PAD in subjects (N = 9816)
with moderate cardiovascular risk and the absence of dia-
betes or overt vascular disease (NCT00689377). The pre-
sent study is a post-hoc analysis performed on the Italian
sub-population of the original PANDORA study [25],
comprising 5112 evaluable subjects from 197 Family Med-
icine Investigation Centers. Inclusion criteria were men
aged ≥45 years or women aged ≥55 years (CVD risk fac-
tor) and the presence of at least one of the following CVD
risk factors: cigarette smoking, hypertension, diagnosed
dyslipidemia, family history of early coronary heart disease
(CHD) or elevated abdominal circumference. Exclusion
criteria included symptoms of PAD, diabetes, established
CHD or risk-equivalents and the absence of fatty serum
data within the past year. The study was approved by local
ethic committees, and informed consent was obtained
from all participants before admission to the study.
Study objectives
In the original study, the primary objective was to deter-
mine the prevalence of PAD, defined as an ABI score of
≤0.90, according to ACC/AHA guidelines for the man-
agement of patients with PAD [1,23,26]. Secondary out-
come variables included the following: frequency of risk
factors (smoking habits, family history of early CHD,
hypertension, low HDL-C, high LDL-C, dyslipidemia,
increased waist circumference, as defined above), and of
lifestyle habits (reduced physical activity) [12,26]; treat-
ment of risk factors; CHD risk assessed according to the
Framingham Point Scores risk chart, based on sex, age,
total cholesterol (TC), HDL-C, smoking habits, systolic
blood pressure and treatment status data [12,27]; risk of
CV death assessed according to the Systematic Coronary
Risk Evaluation (SCORE) risk chart, based on sex, age,
TC, smoking habits, and systolic blood pressure data
[28]; association of PAD with subject and physician fea-
tures as assessed by questionnaires.
Clinical evaluation
Outpatients reported outcomes including a 14-item ques-
tionnaire on awareness of CVD risk factors, knowledge
and awareness of PAD, CVD risk perception and treat-
ment, and frequency of medical consultation was
obtained in a single visit. Furthermore, a 31-items investi-
gator questionnaire was used to investigate demographic
data, and information on knowledge and behaviour in
CVD diagnosis and management, quantity of CVD cases
experienced, general attitudinal statements, guidelines
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gator received training on ABI measurement technique,
according to ACC/AHA guidelines for PAD treatment
[1,23,29]. Right and left ABI measurements were per-
formed at rest assessing the systolic blood pressure from
both brachial, dorsalis pedis and posterior tibial artery,
while the subject stayed in the supine position for 10 min-
utes. Measurements were taken with blood pressure arm-
bands appropriately sized to the subject’s lower calf
(immediately above the ankle). A hand-held Doppler
ultrasonography instrument Elite 100R, Nicolet Vascular
Inc. (Golden, Colorado, USA), with a 8 MHz vascular
probe, was used in all the centres. Right and left ABI
values were calculated according to ACC/AHA guide-
lines [1,23,29]. The primary outcome variable was the
percentage of subjects with PAD, defined as a pathologi-
cal ABI of ≤0.90 measured from thel e f to rr i g h ts i d e .
The original PANDORA study was performed according
to guidelines laid down in the Declaration of Helsinki,
are consistent with ICH/Good Clinical Practice, applic-
able regulatory requirements and the AstraZeneca policy
on Bioethics.
Sample size and statistical analysis
Statistical analysis was performed with SAS version 8.2
software (SAS Institute Inc., Cary, NC, USA). Data are
presented as mean ± SD and/or range and frequency was
expressed as a percentage. Groups were compared using
the c
2 test. For the original PANDORA study [25], the
frequency (%) of the study endpoint with a two-sided
99% confidence interval (CI) of ≤1% was determined.
Based on an expected 15% frequency of pathological ABI
in the selected population [30], a minimum sample size
of 8, 454 evaluable subjects was required to be able to
reach study objectives, and a total population of 9, 000
subjects was therefore planned to be admitted. To exam-
ine the relationships between abnormal ABI and lifestyle
habits or cardiovascular risk factors, the Odds ratio (OR)
and 95% CI of frequency of risk factors and lifestyle
habits in subjects with ABI ≤0.90 and ABI > 0.90 were
calculated and differences between groups were tested by
the Cochran-Mantel-Haenszel test. The relationship
between PAD (defined as presence of ABI ≤0.90) and the
features of patients admitted and family doctors partici-
pants was assessed by logistic regression with backward
selection of covariates, with calculation of OR and 95%
CI. Subject data were investigated among the following
variables: country, demographics (age, sex, ethnic origin,
marital status), CVD risk factors and lifestyle habits
(smoking habits, alcohol intake, physical activity, family
history of early CHD, hypertension, diagnosed dyslipide-
mia, waist circumference, high LDL-C, low HDL-C), and
treatment with lipid-lowering drugs. The primary analy-
sis was performed on evaluable subjects. All subjects
admitted to the study signed informed consent, had no
protocol violations, had an ABI measurement and > 80%
of data collected in subject record forms. A value of p <
0.05 was considered statistically significant; N values
refer to the number of patients examined.
Results
From a total of 10, 287 subjects admitted to the original
PANDORA study, 5, 298 of these subjects were enrolled
in Italy (51.6% of total) from May 2007 to July 2008.
Among admitted subjects, 96.5% (N = 5, 112) were consid-
ered evaluable. The most frequent reasons for exclusion
were: a) less than 80% of CRF fields completed (2.45%), b)
unmeasurable ABI (2.36%) and c) a lack of serum lipid
data collected within the previous 12 months (0.68%).
Baseline demographic and clinical characteristics for
evaluable subjects with and without PAD are summarized
in Table 1. Both groups of patients with and without
PAD were well matched for age and gender. Almost all
subjects were Caucasian (99.51%), approximately half
were male gender (50.69%) and the mean age was
64 years. Significant differences were observed between
subjects with and without PAD for several parameters
measured. PAD subjects had significantly increased blood
pressure (SBP and DBP, p < 0.0001) and heart rate (p <
0.0001). Furthermore, the proportion of patients with
hypertension, family history of early CHD and high alco-
hol intake was significantly higher in PAD subjects.
Serum lipids and lipid modifier medication (including
statins) were also significantly different between subjects
with and without PAD. Interestingly, a significant lower
proportion of patients with PAD were married or living
together compared to patients without PAD (68% versus
79.7%. p < 0.0001). Likewise, the percentage of subjects
separated or divorced were significantly higher in the
PAD group (no PAD compared to PAD respectively;
3.91% versus 13.94%, p < 0.0001).
Among the 6 participating countries of the previous
PANDORA study, a higher prevalence of PAD was
observed in Greece (28.0%) and Italy (22.9%), rather
than in France (12.2%),
Belgium (7.0%), the Netherlands (8.1%) or Switzerland
(12.2%). Multiple logistic regression analysis confirmed
that after Greek subjects, Italians had a greater risk of
PAD (Figure 1).
Distribution of ABI values in all Italian subjects is
shown in Figure 2. Overall, 22.9% of subjects had an
ABI ≤0.9 and another 23.9% between 0.91-0.99.
Approximately half of subjects observed had an ABI >
0.99 (53.23%).
We next evaluated the relationship between PAD and
individual subjects determinants (country, age, sex, race,
marital status), lifestyle habits (alcohol intake, physical
activity), and CVD risk factors (smoking, family history
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Page 3 of 10Table 1 Demographic and clinical characteristics of evaluable subjects with and without PAD
Clinical characteristics No PAD (N = 3, 943) PAD (N = 1, 169) P value
Weight (Kg) 76.5 ± 14 77.1 ± 14.3
Waist circumference (cm) 98 ± 12 97.9 ± 12.8
BMI (Kg/M
2) 27.8 ± 4.3 27.8 ± 4.5
SBP (mmHg) 136.4 ± 14.6 141 ± 14.6 < 0.0001
DBP (mmHg) 81.6 ± 8.3 83 ± 8.2 < 0.0001
Heart rate (beats/min) 72.8 ± 8.7 74.2 ± 8.2 < 0.0001
Age (years, mean ± SD) 63.9 ± 8.7 64.1 ± 9.2
Median 63 64
Interquartile range 58-70 58-70
Age class (%)
45-54 years 11.4 12.8
55-64 years 44 41
65-74 years 32.3 32.1
75-84 years 11.2 12.2










Single (unmarried) 4.9 4.5
Married or living together 79.7 68 < 0.0001
Widowed 11.4 13.5
Divorced or separated 3.9 13.9 < 0.0001
Other 0.1 0.1
Anamnesis (%)
Hypertension 73.7 77.3 0.016
Dyslipidemia 45.2 37.6 < 0.0001
Cigarette smoking 30.2 25.2 0.0008
High alcohol intake 6.1 8.1 0.015
Family history of early CHD 17.4 41.8 < 0.0001
Sedentary lifestyle 64.7 61.2
Serum lipids (mg/dl)
Total cholesterol 216.3 ± 39.2 216.9 ± 38.3
HDL-cholesterol 53.7 ± 13.4 51.9 ± 12.9 < 0.001
LDL-cholesterol 134.4 ± 35.4 134.8 ± 35.4
Triglycerides 138.6 ± 62.7 156.4 ± 70 < 0.0001
Medication (%)
Antihypertensive 54.5 60.05 0.003
Other CV drug 7.23 5.82
Any lipid modifiers 18.18 14.29 0.002
Statin treatment 11.6 6.5 < 0.0001
Data are presented as mean ± SD or % where indicated. BMI = body mass index, CHD = coronary heart disease, SBP = systolic blood pressure, DBP = diastolic
blood pressure.
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ence, dyslipidemia diagnosis and treatment, high LDL-C,
low HDL-C, statin treatment). Multiple logistic regres-
sion did not yield any difference regarding gender, race,
physical activity, elevated waist circumference, dyslipide-
mia, high LDL-C levels or BMI. Variables significantly
associated with PAD are shown in Figure 3
To examine the cumulative impact of CVD risk fac-
tors on presence or absence of PAD, summary statistics
of the 10-year CHD risk were calculated according to
the Framingham risk score (Table 2). The Framingham
10-year CHD risk score was higher in subjects with
PAD compared to those without PAD, in terms of both
mean and median values and risk frequency distribution.
PAD subjects also showed a higher frequency in the
high-risk class (> 20%) compared to subjects without
PAD (23.95% PAD versus 15.98% without PAD).
To explore risk factor burden, the cumulative number
of CVD risk factors in each subject was analysed. In
addition to age, most subjects (with or without PAD)
presented 2 or 3 CVD risk factors (Figure 4A). When-
ever subjects were evaluated for the presence of ≤2o r>
2 risk factors, the frequency of PAD was higher with the
presence of 2 risk factors (Figure 4A, inset). Therefore,
the frequency of subjects with PAD and without PAD
was greatest in the SCORE 10-year CV death risk class
(> 2%) (Table 3). However, frequency of PAD subjects
was higher than subjects without PAD for high-risk
classes (3-4%, 5-9% and 10-14%).
The association between PAD and the number of
CVD risk factors (in addition to age), expressed in terms
of OR ± 95% CI estimates of frequency of ≥2r i s kf a c -
tors compared to 1 risk factor is shown in Figure 4B.
Subjects presenting ≥2 CVD risk factors in addition to
age (i.e. ≥3 CVD risk factors) are more affected by PAD
compared to subjects with only 1 additional risk factor
(p < 0.0001, Cochran-Mantel-Haenszel test).
Concomitant use of other cardiovascular drugs was
similar in subjects with PAD than in those without PAD
(5.82% vs 7.23%). The quantity of subjects receiving
Figure 1 Comparison of risk of PAD between other European
countries compared to Italy. Multiple logistic regression model of
statistically significant regressors. Data presented as odds ratio
(upper and lower 95% confidence intervals). P values refer to level
of statistical significance. Data derived from original PANDORA study
(N = 9816).
Figure 2 Distribution of ABI in Italian subjects.D a t aa r e
presented as percentage distribution, actual values are represented
in parentheses.
Figure 3 The association between PAD and number of
individual CVD risk factors. Multiple logistic regression model of
statistically significant regressors. Data presented as odds ratio
(upper and lower 95% confidence intervals). P values refer to level
of statistical significance. Data based on Italian sub-population from
original PANDORA study (N = 5112).
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(54.5% vs 60.05%). However, statin therapy was signifi-
cantly associated with absence of PAD (Figure 3).
Discussion
This post-hoc analysis of the PANDORA Study repre-
sents the largest study on the general Italian population
to date that has focussed on the prevalence of asympto-
matic PAD in the community setting. Previously,
another study investigated the prevalence of PAD in Ita-
lian subjects, but only patients with symptomatic PAD
were evaluated [20]. The present study is in agreement
with findings from the original PANDORA study since
it confirms the prevalence of a low ABI in patients who
would otherwise be classified as intermediate and even
low CV risk [25]. The prevalence of asymptomatic PAD
within the Italian population was 22.9%. Limited use of
statins in the total cohort of Italian subjects (10.5%) was
also confirmed within the subgroup diagnosed with dys-
lipidemia (24%). Other participant countries had a
higher percentage of patients on statins. The risk of
developing PAD is also increased in subjects with a
higher consumption of saturated fatty acids [31], which
is common in northern Europe [32]. In contrast, risk is
reduced in subjects with higher intake of cereal fiber,
Vitamin E and wine consumption [31,33,34], which are
typical components in the so-called “Mediterranean
diet” [32]. These food preferences in Italian people may
have a favourable action to decrease cardiovascular risk
for PAD. Although gender was equally matched in the
present study, this may be a potential factor to consider
when comparing across differences in other European
countries. However, two separate studies, performed on
a Turkish and a US population respectively, have
demonstrated that the prevalence of PAD does not vary
by gender [22,35]. Subjects without symptoms of the
lower limbs and overt CV disease who are at risk of
PAD, including those less than 50 years with diabetes
and one additional risk factor (smoking, dyslipidemia,
hypertension, or hyperhomocysteinemia), or aged 50 to
69 with a history of smoking or diabetes, or aged 70 and
older need to be further screened for PAD
as highlighted in the PARTNERS study [19]. These
patients need to be submitted to clinical, diagnostic and
instrumental assessment, according to recommendations
mainly derived from the PARTNERS study [19]. Another
Figure 4 The association between PAD and the number of CVD
risk factors. A, The frequency of CVD risk factors (1-5 risk factors) is
shown for patients with no PAD (open bars) and patients with PAD
(filled bars). Inset, % patients (presence or absence of PAD) with ≤2o r
> 2 risk factors. B, Association between risk of PAD and the number
of CVD risk factors in addition to age. Data expressed as Odds ratio (±
95% CI). Comparisons were made between estimates of frequency
distribution of the number of risk factors (i.e. ≥2 risk factors vs 1 risk
factor) by Cochran-Mantel-Haenszel test.
Table 2 Summary statistics of 10-year CHD risk - according to Framingham algorithm in the Italian population with
and without PAD
CHD risk No PAD (N = 3, 943) PAD (N = 1, 169)
Mean ± SD 12.98 ± 8.10 14.68 ± 8.49
Risk score Median 12 14
Interquartile range 0-30 1-30
< 10% 38.68 32.85
Risk class 10-20% 45.35 43.2
> 20% 15.98 23.95
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outpatients in Primary Care, aged ≥65 years, who under-
went ABI testing by family physicians in 344 centres,
showed a prevalence of PAD of 18% [36,37]. This fre-
quency is in agreement with results of the present study,
even though in the Get ABI study 2.8% of the subjects
with low ABI had PAD symptoms. In addition, risk pro-
file in the Get ABI population showed differences from
that of PANDORA, which was due to fewer previous car-
diovascular events or the presence of diabetes. Neverthe-
less, as evidenced by PANDORA, the Get ABI also
confirmed the usefulness of expanding measurement of
ABI over to other risk categories beyond those indicated
by guidelines. A more recent study performed in Turkey
showed a 20% prevalence of PAD, corroborating findings
observed in our study [22]. Moreover, demographic and
clinical characteristics of this Turkish population were
similar to the Italian cohort (i.e., age, gender ratio, asso-
ciated risk factors, etc.), suggesting that a relatively high
prevalence of PAD can be observed in other Mediterra-
nean-like lifestyles. Previous data reported from the
National Health and Nutrition Examination Study
(NHANES; 1999-2004) showed a 3% prevalence of low
ABI in the low or intermediate risk population [38].
Furthermore, Sumner et al. analyzed data from three
NHANES between the years 1999 -2004 and showed that
the prevalence of PAD is consistently increasing in
asymptomatic adults in the US population. Prevalence
rose from 3.7 to 4.6% (p = 0.001) over a six year period
[39]. Marked differences between these results and those
from the PANDORA study were observed, where even in
countries with minimal prevalence of low ABI, frequen-
cies of over 3% were reported, thus emphasizing the need
for periodical measurement of ABI in many risk-groups.
There are some notable findings resulting from this
study, such as the relationship between restricted use of
s t a t i n sa n dt h ep r e v a l e n c eo fl o wA B I .T h ew e l lr e c o g -
nised beneficial prognostic effect of statin treatment on
the prevention of vascular events in patients with symp-
tomatic PAD [40] should be emphasized, with the view
to improving their lower extremity motor performance
[41]. Our findings from the PANDORA study show a
possible protective action of statins against the occur-
rence of PAD and may assist in re-evaluating the patho-
genetic role of dyslipidemia in this condition, especially
considering the fact that other characteristics normally
altered by statins, such as inflammation, were not taken
into account.
It is also worth highlighting the association between
marital status and the presence of low ABI, with unmar-
ried or widowed subjects more likely affected by low ABI
than married subjects. This shows unexpected evidence
on the relationship between marital status and prevalence
of PAD, although previous reports have described the
role of marital status, as part of a more general social
support, as influencing clinical symptoms of PAD [42].
Although we have not directly examined what underlying
factors may influence the link between marital status
(divorced/separated/unmarried) and prevalence of PAD,
it is recognised that the rate of depressive symptoms is
increased in these individuals [43,44]. It is well documen-
ted that patients with PAD have a higher rate of depres-
s i o na n dt h a tt h i si sa l s oc o r r e l a t e dw i t ht h er e d u c e d
activity/sedentary lifestyle that they lead [45]. However,
our findings did not reveal any discernible difference in
sedentary lifestyle between patients with or without PAD,
suggesting that this cause-and-effect relationship between
marital status and prevalence of PAD is more complex.
The major interest of psycho-social factors as cardiovas-
cular risk factors is also suggested by these PANDORA
findings [46]. The explanation for the different frequency
distribution of PAD among countries may be related to
the variability of subject characteristics, in terms of both
frequency distribution and type of risk factors, and could
have been influenced by several lifestyle habits [20] in
addition to differences in use of statins between several
countries.
This study has some limitations, including the lack of a
follow-up period on the occurrence of cardiovascular
events, over an appropriate period after ABI assessment,
in subjects presenting with a low ABI but otherwise clas-
sified as being at low or moderate risk and, as such, not
considered candidates for more aggressive preventive
treatment. However, the adverse prognostic implications
of a low ABI (≤0.90) are widely known and are derived
from many previous studies that have definitively con-
firmed this instrumental examination as an independent
predictor of high cardiovascular risk [2,4]. Therefore, the
standard use of Doppler remains indispensable for an
adequate ABI measurement in family practice, as
reported in healthy subjects, patients at risk and patients
clinically suspected for PAD [47]. It should be empha-
sized that most recent epidemiological studies on PAD
h a v eb e e np e r f o r m e do n l y[ 2 1 ]o ra l m o s to n l y[ 3 0 ]i n
Table 3 Summary statistics of 10-year CV risk - according
to SCORE algorithm in the Italian population with and
without PAD
Risk class No PAD (N = 3, 943) PAD (N = 1, 169)
< 1% 192 (4.9) 40 (3.4)
1% 1007 (25.5) 250 (21.4)
2% 1033 (26.2) 299(25.6)
3-4% 853 (21.6) 274 (23.4)
5-9% 754 (19.1) 248 (21.2)
10-14% 79 (2) 51 (4.4)
≥15% 25 (0.63) 7 (0.6)
Data presented as number and (%).
Sanna et al. BMC Cardiovascular Disorders 2011, 11:59
http://www.biomedcentral.com/1471-2261/11/59
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daily clinical practice of the general practitioner. The ABI
value may be limited in some patients because of the cal-
cification of tibial arteries that are less compressible,
resulting in unusually high ABI values (> 1.40) [1]. Data
from a recent study by Cacoub and coworkers [30] in a
subset of 2, 077 patients older than 55 years and with 2
or more cardiovascular risk factors (including diabetes)
in which the ABI was measured by general practitioners
in France, provided a prevalence of low ABI (below 0.90)
of 10.4%, which is similar to that of the French popula-
tion of the PANDORA study, confirming the satisfactory
reliability of the data collected [25]. The results reported
in the present study are in agreement to other previous
studies in the general population [22,36,37]. The preva-
lence of PAD evaluated using the ABI was found to be
18-19% in subjects aged above 55 or 65 years in The
Netherlands, Germany, the UK, and at approximately
30% in patients with selected vascular risk factors in
North America and France [18,19,48-50]. Given the very
high prevalence of PAD, we observed in moderate-risk
patients and the CV morbidity and mortality associated
with PAD [1,2], undoubtedly better public and health
professional awareness would help preserve individual
CV health and achieve public health goals.
Conclusions
This study provides further evidence that a low ABI is
significantly associated with classical CV risk factors.
Compared to other countries (from the original PAN-
DORA study) this Italian population showed a restricted
statin medical prescription and treatment, although it is
unlikely that this effect may alone account for this
increased prevalence. This study indicates the appropri-
ate use of ABI in Family Medicine for the identification
of patients at high risk and therefore allowing early treat-
ment for the reduction of CV-related death.
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